Literature DB >> 9345290

Role of protein kinase C-alpha in activation of ecto-5'-nucleotidase in the preconditioned canine myocardium.

M Kitakaze1, H Funaya, T Minamino, K Node, H Sato, Y Ueda, Y Okuyama, T Kuzuya, M Hori, K Yoshida.   

Abstract

We have reported that activation of protein kinase C (PKC) increases ecto-5'-nucleotidase activity, which may contribute to the infarct size-limiting effect of ischemic preconditioning. Since we have reported that Ca(2+)- and phospholipid-sensitive PKC is activated due to ischemic preconditioning, we further tested 1) whether PKC-alpha or -beta is translocated to the cellular membrane of the preconditioned canine myocardium, and 2) whether activation of PKC contributes to the increase in ecto-5'-nucleotidase activity via phosphorylation-dependent mechanisms. Four times of 5 minutes coronary occlusion separated by 5 minutes of reperfusion (ischemic preconditioning) translocated PKC-alpha to the cellular membrane in the canine hearts, although PKC-beta, -delta, -epsilon, and -zeta were not translocated. The activity of Ca(2+)- and phospholipid-sensitive PKC increased, which was attenuated by the removal of either Ca2+ or phosphatidylserine. Ecto-5'-nucleotidase was also activated in the preconditioned myocardium compared with control. Inhibition of PKC due to GF109203X blunted the activation of myocardial ecto-5'-nucleotidase. Okadaic acid (an inhibitor of phosphatase) enhanced the increases in ecto-5'-nucleotidase activity due to preconditioning, and this enhancement was blunted by GF109203X. We conclude that ischemic preconditioning activates PKC-alpha, and thus ecto-5'-nucleotidase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9345290     DOI: 10.1006/bbrc.1997.7445

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  Relationship between free radicals and adenosine in the mechanism of preconditioning: are they interrelated or independent triggers?

Authors:  T Fukuma; T Miura; K Suzuki; A Tsuchida; Y Nozawa; K Shimamoto
Journal:  Mol Cell Biochem       Date:  2000-08       Impact factor: 3.396

3.  Role of protein kinase C in the reduction of infarct size by N-methyl-1-deoxynojirimycin, an alpha-1,6-glucosidase inhibitor.

Authors:  M Arai; S Minatoguchi; H Kumada; Y Uno; Y Nishida; K Hashimoto; N Wang; G Takemura; T Fujiwara; M Higashioka; K Kuwano; H Fujiwara
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 4.  It is time to ask what adenosine can do for cardioprotection.

Authors:  M Kitakaze; M Hori
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

5.  Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion.

Authors:  Atsushi Kuno; Stuart D Critz; Lin Cui; Victoriya Solodushko; Xi-Ming Yang; Thomas Krahn; Barbara Albrecht; Sebastian Philipp; Michael V Cohen; James M Downey
Journal:  J Mol Cell Cardiol       Date:  2007-05-24       Impact factor: 5.000

6.  The involvement of protein kinase C-ε in isoflurane induced preconditioning of human embryonic stem cell--derived Nkx2.5(+) cardiac progenitor cells.

Authors:  In-Ae Song; Ah-Young Oh; Jin-Hee Kim; Young-Min Choi; Young-Tae Jeon; Jung-Hee Ryu; Jung-Won Hwang
Journal:  BMC Anesthesiol       Date:  2016-02-20       Impact factor: 2.217

Review 7.  Protein kinase C and cardiac dysfunction: a review.

Authors:  Raphael M Singh; Emanuel Cummings; Constantinos Pantos; Jaipaul Singh
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

8.  GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated.

Authors:  Muhammad Aetesam-Ur-Rahman; Joel P Giblett; Bharat Khialani; Stephen Kyranis; Sophie J Clarke; Tian X Zhao; Denise M Braganza; Sarah C Clarke; Nick E J West; Martin R Bennett; Stephen P Hoole
Journal:  BMC Cardiovasc Disord       Date:  2021-05-01       Impact factor: 2.174

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.